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Abstract  
The hyper-immunoglobulin E (IgE) syndromes (HIES) are primary immunodeficiencies 
characterized by the recurrent staphylococcal abscesses, recurrent pneumonia and highly elevated 
serum IgE levels. There are two forms of HIES: a dominant form (AD-HIES) and a recessive form 
(AR-HIES). AD form of HIES is caused by mutations in STAT3 and the AR form is caused by 
mutations in DOCK8 and TYK2. These syndromes have different clinical presentations and 
outcomes. AD-HIES is a multisystem disorder that includes abnormalities of the skin, lungs, 
musculo-skeletal system and dental system. In contrast, these symptoms in patients with AR-HIES 
are missing. AR-HIES patients have severe viral infections and may develop neurological 
complications. This review article discusses the clinical presentation and laboratory findings in both 
forms of HIES, as well as the establishment of diagnose, inheritance, molecular genetics and 
immunological abnormalities of HIES. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Introduction 
 The hyper-immunoglobulin E syndromes 
(HIES) 147060 and 243700 (Mendelian Inheritance in 
Man, a catalogue of inherited diseases) refer to two 
related immunodeficiency disorders that can manifest 
in a variety of ways [1]. Initially, HIES was described 
in 1966 by Davis and Wedgwood, who associated 
staphylococcal skin infections in newborns with what 
they termed the “Job’s syndrome”, along with skin 
lesions lacking typical signs of inflammation (cold 
abscesses) [2, 3].   
 Buckley and colleagues (1972) then further 
characterized the condition by associating severe 
dermatitis, joint hyperextensibility, asymmetric facies 
and especially the highly elevated serum IgE levels 
with it, which lead them to phrase the term “Hyper IgE 
syndrome” [4].  
 In the following years, an ever-increasing 
effort was devoted to identify describe different HIES 
cases [5-8], which revealed additional characteristic 
clinical symptoms and motivated further research into 
the causative mechanisms thereof [9-17], while others 
suggested a genetic inheritance pattern [18].  
 In 2004, Renner et al. distinguished between 
the autosomal recessive (AR) and autosomal 
dominant (AD) HIES forms, based on their clinical 
appearance [19]. 
 Minegishi and colleagues [20] described the 
potential cause for the AR-HIES form, a homozygous 
deletion within the TYK2 gene, in 2006. In continued 
investigations, Minegishi and colleagues identified the 
mechanism underlying AD-HIES by revealing 
heterozygous STAT3 mutations in patients with AD-
HIES [21]. In 2007, Holland et al. found missense 
mutations and in-frame single-codon deletions within 
STAT3 in AD-HIES patients and their families, thereby 
further underscoring the importance of STAT3. They 
concluded that STAT3 mutations are present in 
sporadic and dominant forms of the hyper-IgE 
syndrome [22].  
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 While several studies had identified mutations 
responsible for the AD form of HIES, apart from one 
possible exception, no mutations had been linked to 
the AR-HIES form until 2009. Then, in 2009, Zhang et 
al. reported on a group of AR-HIES patients exhibiting 
homozygosity or compound heterozygosity for 
DOCK8 gene deletions or mutations [23]. Alsum et al. 
identified novel DOCK8 mutations in continued 
investigations of AR-HIES patients [24].  
 The consensus involves the acknowledgment 
of two HIES forms: a dominant and a recessive form 
caused by mutations in either STAT3 or DOCK8 and 
TYK2, respectively.  These two different syndromes 
have distinct presentations and outcomes with only 
elevated IgE serum levels in common.  
 In this review we will address the differences 
between the two HIES forms in terms of clinical 
features, laboratory abnormalities, diagnosis, 
inheritance, molecular genetics and immunological 
abnormalities.  
 
 Clinical characteristics of HIES 
 HIES is a multisystem disorder affecting the 
skin, lungs, musculoskeletal system, the face, central 
nervous system, dentition and the vascular system. All 
of the clinical findings in HIES vary with age and 
among individuals, with further differences arising due 
to the different mutations characteristic of either the 
autosomal dominant HIES (AD-HIES) or the 
autosomal recessive HIES (AR-HIES) form. 
 
 AD-HIES (STAT3 mutations) 
 Skin. A newborn rash is usually the first 
manifestation of AD-HIES. The rash is pustular and 
eczematoid and usually begins within the first month 
of life. It typically affects the scalp and the face first 
[25, 26]. In a group of 43 patients, 19% (8 babies) 
were born with the rash, while in 53% (23 babies) the 
rash appeared within the first week of life [27]. The 
biopsies reveal eosinophilic infiltrates and bacterial 
cultures. Staphylococcus aureus is the most common 
bacteria. The rash often persists throughout 
childhood, but it can be well controlled with 
appropriate therapy. Furuncles are characteristic for 
the diagnosis and are classical findings typical of the 
disease. The severity of inflammatory symptoms is 
often quite variable. The “cold” abscesses are also 
common and even with the absence of the external 
inflammation signs there is apparent pus and again 
Staphylococcus aureus is the most common bacteria. 
 Lung. Recurrent pyogenic pneumonias are 
typical. They usually start in early childhood. The most 
common pathogens are S. aureus, with Streptococcus 
pneumoniae and Haemophilus influenzae also 
occurring frequently [8, 28]. Similarly to the “cold” 
abscesses, individuals often lack systemic signs of 
inflammations. Healing of the pneumonia is often 
complicated with pneumatoceles and bronchiectasis. 
The structural abnormalities persist and are quite 
significant because later they are sites of fungal 
(typically Aspergillus) and Gram-negative (typically 
Pseudomonas) infections. These infections are the 
major cause of morbidity and mortality [29]. Mold 
infections can invade blood vessels leading to life-
threatening hemoptysis and may disseminate to 
extrapulmonary sites of infection. There are also 
opportunistic infections in HIES patients. 
Pneumocystis jiroveci pneumonia was described as 
the initial pneumonia in HIES infants [30].  
 Other infections. Mucocutaneous candidiasis 
is characteristic for patients with STAT3 mutations 
and is typically presented as oral thrush, vaginal 
candidiasis or onychomycosis [8]. Candida infections 
are very rare and in the most cases are nosocomial in 
origin. The uncommon yeast infections are often 
localized as disseminated histoplasmosis of the 
tongue and Cryptococcus infection in the intestinum 
[31, 32]. 
 Musculoskeletal abnormalities and facial 
appearance. Skeletal and facial abnormalities are 
typical only of the AD form of HIES. Some of the 
musculoskeletal abnormalities in HIES patients were 
described and recognized in the original reports by 
Davis et al. in 1966 and Buckley et al. in 1972 [2, 4]. 
Musculoskeletal abnormalities are typical for AD-HIES 
patients and include scoliosis, minimal trauma 
fractures, osteopenia, hyperextensibility and 
degenerative joint disease [8]. Scoliosis occurs in 75% 
of the patients and may develop during adolescence. 
The developing pattern is similar to idiopathic 
scoliosis. It can also develop as a secondary 
complication because of length discrepancy, lung 
disease with volume loss, or lung resections. The 
degree of scoliosis can vary and may be so severe as 
to require surgical treatment. Degenerative joint 
disease, especially of the spine, often manifests in the 
third and fourth decade of life and may require 
surgical repair. Minimal trauma fractures mainly occur 
on the ribs, long bones and pelvic bones. They can 
occur independently of osteopenia. It has been 
suggested that osteopenia, which is common in HIES 
patients, may be cytokine or immune driven, and the 
fractures that occur are not in the same sites which 
are typical of osteoporosis in menopausal females. 
Bone resorption in patients with HIES is unusually 
high and has been attributed to concomitant 
abnormalities in the prostaglandin synthetic pathway 
[33, 34].  
 The facial appearance that is typical only for 
the patients with STAT3 mutations develops during 
childhood and adolescence and it was also noted in 
the very first reports of the disease. The patients were 
described as with unusual faces, with coarse features 
[2, 4]. The face of a HIES patient is unequal, 
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asymmetric and the main typical features are broad 
nose, deep-set eyes and a prominent forehead [7, 8, 
28]. 
 Dental abnormalities. Dental anomalies are 
consistent features of STAT3 patients [8]. They retain 
some of their primary teeth after the normal primary 
dental exfoliation age. It has been suggested that 
reduced resorption of primary tooth roots leads to their 
prolonged retention, which in turn prevents the 
appropriate eruption of the permanent teeth [35].  
 Nervous system. There is craniosynostosis of 
different degrees. Smithwick et al. in 1978 reported 
three HIES cases associated with cranial 
abnormalities and suggested that the abnormalities 
can provide better understanding of the molecular 
mechanisms underlying the impaired regulation of 
immunoglobulin E [36]. The fourth case was reported 
in 1985, where a 9-year-old boy with premature fusion 
of the sagittal and lambdoid suture suffered from 
scaphocephaly [37]. Other recurrent malformations 
include the Chiari 1 malformations. In a study of 50 
HIES patients, Chiari type 1 malformations were found 
in nine, while five patients had lacunar infarctions and 
two patients had infectious complications that were 
shown to be of fungal origin [38]. 
 The eye. Abnormalities of the eye as part of 
the nervous system were also reported. Lee et al. in 
2003 described a 57 year old woman diagnosed with 
HIES at the age of 22 years, with extensive 
xanthelasma [39]. Additionally, ophthalmologic 
pathologies such as giant chalazia were reported [40].  
 Vascular abnormalities. The first report of 
coronary artery aneurysms in AD-HIES was in 2007, 
with the description of two patients (age 43 and 48). 
They both had coronary artery aneurysms identified 
on cardiac catheterization [41]. 
 Malignancies. Lymphomas are most frequent 
in HIES patients. The increased risk of malignancies 
is associated with the AD form of HIES. A case report 
in 1989 described a 7-year-old boy with 
retroperitoneal Burkitt's lymphoma with probable 
metastasis to the brain [42]. After 15 years Leonard et 
al. reported of the case of a 22-year-old male HIES 
patient with a diffuse large B-cell lymphoma involving 
second lumbar vertebrae and spleen. They have 
reviewed reported cases of lymphomas and showed 
that there is an increase in relative risk of 259 (95% 
confidence interval 102, 416) [43]. During the same 
year, an additional report documented pulmonary 
adenocarcinoma in a HIES patient [44]. 
 
  AR-HIES (DOCK8 mutations) 
 Skin. Renner ED et al. studied a large group 
of 13 AR-HIES patients originating from 6 
consanguineous families and 68 of their relatives. 
They concluded that the primary clinical 
manifestations of this form are severe eczema and 
recurrent skin infections [19]. Clinical manifestations 
of the skin started early in life, but not necessarily 
during the newborn period. The skin manifestations in 
AR-HIES differs from AD-HIES in the much higher 
incidence of cutaneous viral infections including 
Molluscum contagiosum, herpes simplex and varicella 
zoster virus infections. 
Table 1: Summary of symptoms characteristic of STAT3 AD- 
HIES and DOCK8 AR-HIES. 
AD-HIES AR-HIES
Newborn rash Rash but not necesseraly newborn
Pustular and eczematoid rash Severe eczema and reccurent skin infections
Bacterial infections (S. aureus ) Bacterial infections (S. aureus )
High incidence of viral infections
(including Molluscum contagiosum, Herpes simplex and Varicella Zoster virus)
Reccurent pyogenic pneumonias Reccurent pyogenic pneumonias 
Pathogens: Pathogens: 
Staphylococcus aureus  Staphylococcus aureus  
Streptococcus pneumoniae Haemophilus influenzae
Haemophilus influenzae Proteus mirabilis
Aspergillus Pseudomonas aeruginosa
Pseudomonas aeruginosa Cryptococcus
Pneumocystis jiroveci  
Cryptococcus
Complications of treatment: Complications of treatment:
Pneumatocoeles and bronchiectasis Without pneumatocoeles and bronchiectasis
Mucocutaneous candidiasis Mucocutaneous candidiasis
Rare systemic Candida infections Rare systemic Candida infections 
Scoliosis Absence of abnormalities
Minimal trauma fractures
Osteopenia
Hyperextensibility
Degenerative joint disease 
Face of Job Absence of abnormalities
(unequal, asymmetric, broad nose, deep – set eyes 
and a prominent forehead)
Retention of primary teeth Absence of abnormalities
Craniosynostosis More sypmtomatic neurologic disease
Chiari 1 malformations (from facial paralysis to hemiplegia) 
Extensive xanthelasma
Giant chalazia
Coronary artery aneurysms Eosinphilic vasculitis
Bilateral berry aneurysms of internal carotid arteries
Mycotic anurysm
Association with higher risk of malignancies Lymphoma
Lymphoma
Pulmonary adenocarcinoma
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 Lung. Patients with AR-HIES also have 
sinopulmonary infections and the most common 
pathogens are S. aureus, Haemophilus influenzae, 
Proteus mirabilis, Pseudomonas aeroginosa and 
Cryptococcus. The most significant difference in the 
clinical features of the different mutations causing the 
two HIES forms is that AR-HIES patients heal their 
lung infections without forming pneumatoceles and 
bronchiectasis [19]. 
 Other infections. Mucocutaneous candidiasis 
is also characteristic of patients with DOCK8 and 
TYK2 mutations, as well as oral thrush, vaginal 
candidiasis or onychomycosis [8, 19]. Candida 
infections are very rare and in most cases are of 
nosocomial origin. The uncommon yeast infections 
are often localized, as the already mentioned 
disseminated histoplasmosis of the tongue and 
Cryptococcus infection in the intestinum [31, 32]. 
 Musculoskeletal abnormalities and facial 
appearance. Patients with this form of HIES lack the 
connective tissue and skeletal abnormalities [19].  
 Dental abnormalities. AR-HIES patients have 
normal primary tooth exfoliation [19].  
 Nervous system. The patients with AR-HIES 
have more symptomatic neurologic disease. In a 
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study of 13 affected patients and 68 of their relatives, 
Renner et al. in 2004 found neurologic symptoms in 
seven patients. The symptoms were ranging from 
facial paralysis to hemiplegia [19]. 
 Vascular abnormalities. Freeman et al, 
reported bilateral berry aneurysms of internal carotid 
arteries and mycotic aneurysm as causes of death in 
a HIES patient [29]. It is suggested that the 
neurological complications in AR-HIES may be 
manifestations of possible vasculitis. 
 
 AR-HIES (TYK2 mutations)  
 There are only two known TYK2 HIES cases 
described in the literature [20, 45].  One of the 
patients had a history of infantile atopic dermatitis with 
recurrent infections, such as otitis media, sinusitis, 
pneumonias, and skin abscesses, starting from 12 
months of age. Ten months later he developed BCG 
lymphadenitis. He experienced Staphylococcus 
aureus bacterial infections, as well as viral and fungal 
infections, such as molluscum contagiosum, herpes 
simplex infection of skin and mucosa, and oral 
candidiasis. The patient developed severe non-Typhi 
Salmonella gastroenteritis leading to sepsis. The 
patient did not have any skeletal abnormalities. This 
TYK2 deficient patient was phenotypically distinct 
from the other autosomal recessive HIES patients with 
DOCK8 mutations, having non-Typhi Salmonella 
infections and BCG lymphadenitis, because of which 
Minegishi et al. proposed that this case represents a 
subset of the AR-HIES form [20].  
 The second patient did not have atopy, 
asthma, skin candidiasis, boils, folliculitis, or cold 
abscesses.  However, the patient developed two 
disseminated infections with intracellular organisms, 
the first one of which occurred 6 months after BCG 
vaccination at an age of 8 months, when axillary 
lymphadenopathy was diagnosed, while the second 
was a Brucella spp. infection that took place 7 years 
later. After the infection, the patient had an episode 
with left temporal, occipital, and bilateral parietal brain 
infarcts accompanied by sensorineural hearing loss 
and residual cognitive impairment. Later, the patient 
had severe herpes zoster infection [45].  
 
Laboratory Findings 
 AD-HIES (STAT3 mutations) 
 The main laboratory finding of HIES is the 
abnormally high IgE level in the serum that may 
exceed 2000 U/ml, even reaching 100 000 U/ml [8, 
46, 47]. For the diagnostic perspective, increased IgE 
levels are very helpful in establishing HIES, for which 
the 2000 U/ml IgE concentration may be used as a 
cut-off point [48], including cases where patients 
suffer from multiple conditions [49].  
 However, elevated IgE levels alone are not a 
sufficient, as they are not always present in patients, 
especially in infants, or are even normal [8]. This is 
exemplified by a HIES case report of two girls in India 
(6- and 12-year-old) where the general conclusion 
was that mildly elevated IgE levels do not exclude the 
HIES, especially when other typical symptoms of it are 
present [50]. 
 Another AD-HIES hallmark is blood 
eosinophilia, where the eosinophil count does not 
correlate with IgE levels. The eosinophil count in 
peripheral blood exceeds 700 cells/microliter or a rise 
that is at least 2 SD above the normal range [47, 51]. 
 In the majority of cases with AD-HIES the 
levels of the other immunoglobulin classes are normal 
[47, 52].  
 In 1979 Schopfer et al. reported the presence 
of Staphylococcal IgE antibodies and later in 1983 
they described a case of Staphylococcus aureus HIES 
with systemic lupus erythematosus as a late 
complication. The main goal was to examine the 
antinuclear autoantibodies and they reported the 
presence of specific antistaphylococcal and 
anticandidal IgE antibodies [53, 54]. On the other 
hand, several years later there were reports of AD-
HIES patients, where the existence of elevated, 
specific IgE antibodies towards Staphylococcus and 
Candida was interpreted as the first sign of infection 
typical for HIES patients [55]. However, these findings 
can also be present in patients with atopic dermatitis, 
which further underscores the necessity to involve 
multiple factors when diagnosing HIES [56].  
 
 AR-HIES (DOCK8 mutations) 
 In AR-HIES, elevated IgE serum levels, as 
well as eosinophilia are more pronounced than in the 
AD form of HIES (43), while IgM levels in patients with 
a DOCK8 deficiency are low [57].  
 Lymphopenia affected CD4 and CD8 cells in 
the DOCK8 AR-HIES patients, where the CD8 T cells 
failed to activate, divide and expand [57].  
 
 AR-HIES (TYK2 mutations)  
 Laboratory findings revealed mild eosinophilia 
(700–800/mm3) and high serum IgE (2100 IU/ml) with 
normal amounts of other Ig classes and subclasses in 
the first described patient with TYK2 defects. All other 
laboratory data examined were within the normal 
range, including complement components, oxidative 
burst of granulocytes, number and size of platelets, 
lymphocyte subpopulations, and their proliferative 
responses to mitogens [20].  
 Laboratory assessment of the second patient 
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Table 2: Scoring system with Clinical and Laboratory Tests for Individuals in Kindreds with HIES. 
   
 
CLINICAL FINDINGS 
POINTS
a 
0 1 2 3 4 5 6 7 8 10 
Highest serum-IgE level (IU/ml)
b
 < 200 200-500   501-1,000    1,001-
2,000 
>2,000 
Skin abscesses None  1-2  3-4    >4  
Pneumonia (episodes over lifetime) None  1  2  3  >3  
Parenchymal lung abnormalities Absent      Bronchiect
asis 
 Pneumato
cele 
 
Retained primary teeth None 1 2  3    >3  
Scoliosis, maximum curvature < 10º  10-14º  15º-20º    >20º  
Fractures with minor trauma None    1-2    >2  
Highest eosinophil count (cells/l)
c
 < 700   700-800   >800    
Characteristic face Absent  Mildly 
present 
  Present     
Midline anomaly
d
 Absent     Present     
Newborn rush Absent    Present      
Eczema (worst stage) Absent Mild Moderate  Severe      
Upper respiratory infections per year 1-2 3 4-6  >6      
Candidiasis None Oral Fingernail
s 
 Systemic      
Other serious infections None    Severe      
Fatal infection Absent    Present      
Hyperextensibility Absent    Present      
Lymphoma Absent    Present      
Increased nasal width
e
 <1 SD 1-2 SD  >2 SD       
High palate Absent  Present        
Young - age correction >5 years   2-5 years  1-2 years  ≤1 year   
a 
The entry in the furthest-right column is assigned the maximum points allowed for each finding; 
b
 Normal < 130 IU/ml; 
c 
700/l = 1 SD, 800/l = 2 SD above the mean value for normal 
individuals; 
d 
For example, cleft palate, cleft tongue, hemivertebrae, other vertebral anomaly, etc. (see Grimbacher et al.1999a); 
e 
Compared with age - and sex - matched controls (see 
Farkas et al. 1994). 
 
 
 
 
with TYK2 defects during chronic infection 
demonstrated normal nitroblue tetrazolium test, 
normal serum IgG, IgM, IgA, and mildly elevated IgE 
[45].  
 
Diagnosis 
 In 1999, the National Institutes of Health (NIH) 
developed a scoring system for AD- HIES diagnosis in 
patients and their families [27]. The scoring system is 
based on clinical and laboratory test criteria (Table 2). 
 The assigned points are based on the 
incidence and specificity of the various AD-HIES 
diagnostic markers. The more specific AD-HIES 
features in Table 2 have bigger importance than 
findings of lower specificity or are common in the 
general population. 
 Table 2 illustrates the estimation of common 
findings in AD-HIES patients which we have 
previously described here. However, some of them 
cannot be confirmed in young children due to later 
onset (scoliosis, face of Job, retained primary teeth). 
Furthermore, the number of infection episodes and 
fractures in AD-HIES patients increases with their 
age. That is why this scoring system includes a 
correction for the age, thereby avoiding false-negative 
scores in children.  Studies that are more recent 
require a score of 40 as an inclusion criterion, since 
the NIH scoring system is prone to high variability 
[58].  
Table 3: Scoring system that can be applied towards 
categorizing potential HIES patients. 
Points Presence of HIES  
≥ 15 Likely present 
10-14 Indeterminate 
< 10 Unlikely present 
 The patients in this study were divided based 
on this scoring system in several groups (Table 3).  
 
Inheritance 
 Initial studies of subsequent generations 
exhibiting infections, rash and eosinophilia done by 
Blum [59] and later the studies by Buckley and Backer 
[10] lead to the proposal of an autosomal dominant, 
gender-independent inheritance pattern of HIES. This 
was later confirmed in a larger study by Grimbacher et 
al. further establishing that HIES is inherited in an 
autosomal dominant manner with variable expressivity 
[8]. 
 However, previously Leung et al. suggested 
that the AD form of HIES may also be of sporadic 
origin, completely lacking family history or 
consanguinity [60]. In 2004, Renner et al. described 
an autosomal-recessive form of HIES, thereby 
establishing a different, previously unrecognized 
disease entity that may be genotypically unrelated to 
AD-HIES [19]. 
 Even though most of the cases are of 
sporadic origin, we can recognize the AD and AR 
forms of HIES [47], which in turn may be also referred 
to as type 1 and type 2 HIES [61]. 
 
Molecular Genetics 
 AD-HIES (STAT3 mutations) 
 In 1999, Grimacher et al. [27] evaluated 19 
families affected by heterogenous AD- HIES variants. 
Aside from the scoring of the clinical and laboratory 
findings, they genotyped the family members with 
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polymorphic markers specific for a possible candidate 
region on chromosome 4. They selected this 
chromosome region because of a previous case 
report of a 17-year old male with AD-HIES, autism 
and mild mental retardation. In this report, Grimbacher 
et al. discovered an extra, abnormal chromosome in 
the male’s peripheral blood lymphocytes and skin 
fibroblasts. Further investigations of the chromosome 
revealed that it was derived from a small, interstitial 
deletion of a homologue of chromosome 4q21. 
Therefore, they suggested that the proximal 
chromosome 4q can be a candidate region containing 
diseased genes affecting both HIES and autism [62]. 
 Grimbacher et al. conducted a statistical test 
(LOD score) based on data from members of the 19 
families to establish whether the various loci under 
investigation are linked to each other. Positive LOD 
scores favor the presence of linkage, whereas 
negative LOD scores indicate that linkage is less likely 
[63]. They found a maximum LOD score of 3.61 with 
marker D4S428, with recombination factor θ = 0.0. 
 Further tests confirmed that the proximal 4q region 
contains a disease locus for the syndrome and the 
fact that six probands did not show linkage to 4q, 
indicated genetic heterogeneity. 
 Minegishi and colleagues identified the 
molecular mechanism underlying AD-HIES in 2007 
when they identified heterozygous STAT3 mutations 
in eight out of fifteen unrelated non-familial HIES 
patients. They showed that these dominant-negative 
STAT3 mutations resulted in the AD form of HIES 
[21]. The analysis of the patients’ parents and siblings, 
however, did not reveal mutant STAT3 alleles and 
lead Minegishi et al. to propose that these are de novo 
mutations. They identified five different mutations in 
the STAT3 DNA-binding domain. In the patients’ 
peripheral blood cells they found impaired responses 
to cytokines, including IL-6 and IL-10, which indicated 
the involvement of multiple cytokine pathways in the 
pathogenesis of AD-HIES. 
 A month later in 2007, Holland et al. reported 
on a longitudinal study based on clinical data obtained 
from AD-HIES patients and their families [22]. They 
measured cytokine levels exuded by stimulated 
leukocytes and also quantified gene expression in 
resting and stimulated cells. The data revealed an IL-6 
signaling pathway defect related to downstream 
signaling mediators and one of which is STAT3. 
Further sequencing of STAT3 from their patients 
revealed missense mutations and single-codon in-
frame deletions. They identified eighteen discrete 
mutations, five of which were hotspots, that modulate 
DNA binding and SRC homology 2 (SH2) domains. 
The mutations that were found in this study are 
presented in Figure 1 [22]. Holland et al. also 
concluded that STAT3 mutations are present in the 
sporadic and dominant forms of the hyper-IgE 
syndrome. 
 
Figure 1:  STAT3 Mutations. Wild-type amino acids at the loci 
where mutations were found are listed immediately below the 
STAT3 domains, with all the mutant amino acids identified in our 
study listed below that. The five hot-spot sites, those with multiple 
mutations, were found in both the DNA-binding and SRC homology 
2 (SH2) domains. The amino acid mutations shown (and the 
underlying nucleotide mutations) in the DNA-binding domain are as 
follows: R382W (1144C→T), R382Q (1145G→A), R382L 
(1145G→T), F384L (1150T→C), F384S (1151T→C), R423Q 
(1268G→A), V463del (1387delGTG), and S465A (1393T→G). The 
amino acid mutations shown (and the underlying nucleotide 
mutations) in the SH2 domain are as follows: S611N (1832G→A), 
F621V (1861T→G), T622I (1865C→T), V637M (1909G→A), V637L 
(1909G→T), P639A (1915C→G), Q644del (1930delCAG), N647D 
(1939A→G), E652K (1954G→A), and Y657C (1970A→G). 
 
 The identification of the STAT3 mutations in 
the AD form of HIES has enabled us to see more 
deeply into the pathogenesis of this disease, as well 
as to correlate the clinical manifestation to the 
accompanying laboratory findings.  
 
 AR-HIES (DOCK8 mutations) 
 With much effort being invested into the 
discovery of the genetic basis of HIES, only the AD-
specific mutations were determined by 2009. Then, 
Zhang et al. reported of gene mutations in 11 patients 
with AR-HIES, in whom they were unable to detect the 
DOCK8 protein [23]. More recently, novel DOCK8 
mutations and two large deletions were described in a 
2013 study by Alsum et al., which was based on a 
much larger group of patients [24].  
 
 AR-HIES (TYK2 mutations) 
 In 2006, Minegishi et al. described an AR-
HIES patient, in whom they identified a homozygous 
deletion of the GCTT sequence at nucleotide 550 in 
the TYK2 gene. The deletion resulted in a frameshift 
and premature truncation of the protein so that they 
could not detect the TYK2 protein in the patient’s T 
cells. The patient's parents were heterozygous for the 
TYK2 mutation and they were healthy [20]. 
 This was a reason for Woellner et al. (2007) 
to analyze TYK2 in 15 additional families with AR-
HIES. However, they failed to identify mutations and 
concluded that the TYK2 deficiency is genetically 
distinct from AR-HIES [64]. In a response, Minegishi 
et al. (2007) noted that analysis of exon coding 
regions and the adjacent intronic sequences is not 
sufficient to identify all genetic alterations, so they 
suggested that further analysis is needed to exclude a 
TYK2 deficiency as the cause of AR-HIES in these 
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patients [20]. 
 The second diagnosed TYK2 AR-HIES case 
was a patient of Turkish descent. He had an early 
termination codon in TYK2 at amino acid position 767 
caused by a nine base-pair DNA deletion in exon 16. 
As a result, there was no detectable full-length TYK2 
protein [45]. 
 
Immunological Abnormalities 
 AD-HIES (STAT3 mutations) 
 There are different immune system disorders 
in HIES patients, including defective neutrophil 
chemotaxis, defective production of IFN-γ by T cells, 
defects in the Th1-dependent cytokine response, 
distortion of Th1/Th2 cell ratio, decreased memory T 
cell population, reduced delayed-type hypersensitivity 
responses [28]. But all of these different disorders 
failed to explain the susceptibility to specific infections 
that are seen in AD-HIES, some of which were 
reported by Milner et al. in 2008. They showed that 
patients with the AD form of HIES had low IL-17 
production by T-cells. They studied three subject 
groups: healthy controls with no evidence of 
immunological defects, HIES patients with mutations 
in STAT3 and individuals (which they named ‘HIES - 
like’) with some combination of increased IgE levels, 
atopic dermatitis, skeletal abnormalities and 
susceptibility to infection, but without STAT3 
mutations. They noted that individuals with AD-HIES 
lacked IL-17 production, but not IL-2, tumour-necrosis 
factor or interferon-γ, in response to mitogenic 
stimulation with staphylococcal enterotoxin B or to 
antigenic stimulation with Candida albicans or 
streptokinase. They showed that purified, naive T cells 
were unable to differentiate into IL-17-producing 
(TH17) T helper cells in vitro [65]. IL-17 plays an 
essential role in antimicrobial protection, because IL-
17 increases the number of neutrophils and expands 
antimicrobial peptides. Th17 cells produce 
proinflammatory cytokines involved in innate immunity 
(TNFa, IL-22, IL-26, IL-6). With this fundamental role 
of Th17 cells, including cells against Candida 
antigens, we can explain the pattern of susceptibility 
to particular infections seen in HIES patients of the AD 
form [66, 67]. Recent studies supported the critical 
role of Th17 cells in the host defense against mucosal 
Candida infection [68]. 
 
Figure 2:  Role of STAT3 (Differentiation of Th17 cells in normal 
defence – left and in STAT3 deficiency-right). 
 Since STAT3 is essential for the signal 
transduction induced by numerous cytokines (IL-6, IL-
10, IL-11, IL-17, IL-21 and IL-22), a deficiency thereof 
will lead to upregulation of many Th1 cytokines and 
downregulation of pro-inflammatory and anti-
inflammatory responses regulated by IL-6 and IL-10, 
respectively [22]. However, IL-10 and IL-21 induce 
differentiation of B cells into Ab-secreting cells (69), 
implying that aberrant STAT3 downstream signaling 
may be responsible for defective Ag-specific Ab 
responses in AD-HIES patients. 
 
Figure 3: Ag-specific response in normal defence – left and in 
STAT3 deficiency-right. 
 
 Patients with AD-HIES had skeletal 
abnormalities that are not characteristic for the AR 
form. Leung et al. (1988) discovered an increased 
ability of monocytes to resorb bone in HIES patients 
when compared to healthy individuals [33]. Monocyte-
mediated bone resorption can be stimulated by TNF-α 
and IL-1β [70]. Evidence from STAT3-deficient murine 
myeloid cells showed that they produce high 
quantities of TNF-α and IL-1β [71]. It is likely then that 
skeletal abnormalities in AD-HIES patients develop 
because of the increased level of these cytokines [33].  
 The cause for the highly elevated IgE levels 
was investigated through the generation of an IL-21R 
deficient mouse, where the finding of high IgE levels 
was associated with the role of STAT3 in mediating 
IL-21 receptor signaling [22, 72].   
 
 AR-HIES (DOCK8 mutations) 
 DOCK8-deficient patients exhibit multiple 
abnormalities of the immune system, including high 
serum IgE, eosinophilia, lymphopenia and antibody 
abnormalities. As lymphopenia affects both CD4 and 
CD8 T cells, Zhang et al. examined the T cells 
responses after in vitro stimulation of the T cell 
receptor in 11 cases of undefined, combined 
immunodeficiency or autosomal recessive hyper-IgE 
syndrome where they established a DOCK8 
deficiency [23]. They also investigated functional 
defects in CD8 T cells, where they found that CD8 T 
cells from DOCK8-deficient patients fail to activate, 
divide, and expand. Because of the antiviral role of the 
T cells, they measured antiviral cytokines IFN-γ and 
TNF-α, which they found to be decreased as well. 
This can explain the increased susceptibility of 
DOCK8-deficient AR-HIES patients to viral infections.  
 A second explanation of lymphopenia in 
DOCK8-deficient patients may be that DOCK8 plays a 
role in T cell migration. The role of DOCK180-related 
family members in chemotaxis is well known and may 
help to associate it with the increased susceptibility to 
cutaneous, but not systemic viral infections in most 
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DOCK8-deficient patients. 
 In addition to their lymphopenia, DOCK8-
deficient patients have antibody abnormalities. 
Besides their elevated serum IgE, which could be a 
result of a selection bias, patients have low IgM. In 
two patients who were immunized with neoantigen 
bacteriophage, a secondary challenge failed to elicit 
isotype class switching or memory responses, 
suggesting possible defects in T cell induced B cell 
functions [23]. 
 In 2009, Al Khatib et al. provided experimental 
evidence suggesting that the DOCK8 deficiency 
coincided with defects in Th17 cells, which could be 
used to explain the susceptibility to Candida infections 
in AR-HIES patients [73]. 
 
 AR-HIES (TYK2 mutations)  
 Minegishi et al. in 2006 described an AR-
HIES patient with TYK2 mutations [20]. They 
examined the immunological defects in this patient 
and suggested that in the absence of TYK2, IL-12 and 
type I IFN signaling are abnormal leading to 
diminished Th1 differentiation and IFN-γ production. It 
is most likely that this defect is responsible for the 
susceptibility to intracellular bacterial infections, which 
is the main difference between the DOCK8 AR-HIES 
and TYK2 AR-HIES. The defect in type I IFN signaling 
results with susceptibility to herpes virus infections 
[21]. 
 
Conclusion 
 The attempt to relate HIES-specific genetic 
and molecular markers with the observed clinical 
infectious phenotype has proven to be very effective. 
The combination of a basic scientific and a clinical 
approach appears to be essential for establishing new 
knowledge regarding fundamental immunological 
mechanisms. Patients with HIES require constant 
surveillance regarding infections and chronic lung 
disease. With early diagnosis, the distinction of the 
two forms and treatment of infections, most patients 
with HIES can lead full lives, and become productive 
adults. 
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